Parenteral Nutrition Market to 2018

Transcription

1 Parenteral Nutrition Market to 2018 Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth

2 GBI Research Report Guidance GBI Research Report Guidance Chapter two provides an introduction to the PN market. Chapter three provides an introduction to the PN market. It describes clinical nutrition and provides an overview to PN guidelines. Chapter four includes revenue forecasts for and describes in detail the major drivers and barriers for the market. Chapter five includes revenue forecasts for the US, the top five countries of Europe (the US, Germany, Italy, France and Spain) and Japan. The chapter also provides analysis of the nutrient market by segment, and the key products for the geographies mentioned above. Chapter six includes an overview and provides revenues and revenue segmentation by geography for amino acids, lipids, carbohydrates and additives. Chapter seven provides detailed information of major marketed products by company. Chapter eight company profiles for six companies. Chapter nine provides detailed descriptions of major M&A, licensing and co-developmental deals. Page 2

3 Parenteral Nutrition Market to 2018: Executive Summary The global Parenteral Nutrition (PN) market was estimated at $XX billion in 2011, indicating a Compound Annual Growth Rate (CAGR) of XX% between 2004 and 2011 Parenteral Nutrition Market to Executive Summary The Parenteral Nutrition Market to Grow at a Compound Annual Growth Rate of XX% in the Forecast Period The global Parenteral Nutrition (PN) market was estimated at $XX billion in 2011, indicating a Compound Annual Growth Rate (CAGR) of XX% between 2004 and The market is expected to grow at a CAGR of XX% between 2011 and 2018 to record a sales value of $XX billion by the end of the forecast period. The figure below shows the market s revenues for Parenteral Nutrition Market to 2018, Global, Revenues ($m), CAGR ( ): XX% CAGR ( ): XX% Revenues ($m) Source: GBI Research, GBI Research Proprietary Database [Accessed May 5, 2012] The primary reasons for the expected high growth rate are the increase in the incidence of diseases that require PN as nutritional support, such as cancer, Acquired Immunodeficiency Syndrome (AIDS) and Gastrointestinal (GI) disorders. The rise in the elderly population is another reason for market growth as this group is more prone to chronic diseases and require more PN support in comparison to the young population. There were XX acquisitions and XX major licensing deals between 2004 and 2012 The PN market has a broad portfolio of products, such as single-dose amino acid solutions, lipid emulsions, carbohydrates, vitamins, minerals, trace elements, electrolytes, and all in one Multi-Chamber Bags (MCBs). Growth Potential in the Parenteral Nutrition Market Favors Acquisitions and Licensing Agreements The Merger and Acquisitions (M&As) and licensing agreements between 2004 and 2012 in the global PN market have remained fairly moderate, with XX acquisitions and XX major licensing deals. Fresenius Kabi participated in XX% of the acquisition deals and XX% of the licensing agreements. The other major players, Baxter and Hospira, accounted for XX% each of the total licensing agreements between 2004 and B. Braun participated in XX% of the licensing agreements during the same period. With a large majority of deals involving approved drugs, this suggests that the market players are showing a strong interest in expanding their existing product portfolios and presence in the worldwide PN markets, rather than focusing on developing new products for the future. Page 3

4 Table of Contents 1 Table of Contents 1 Table of Contents List of Tables List of Figures Parenteral Nutrition Market to Introduction Parenteral Nutrition Market to Overview Clinical Nutrition Enteral Nutrition Parenteral Nutrition Parenteral Nutrition Market to Market Characterization and Forecasts Revenue Forecasts Parenteral Nutrition Market Drivers Increase in the Incidence of Diseases such as Cancer, AIDS and GI Disorders that Require Nutrition Support Increase in the Elderly Population will Drive PN Market Growth The Home Parenteral Nutrition Sector will Witness Strong Market Growth Parenteral Nutrition Market Restraints Reimbursement Regulations will Hinder Market Growth in the US Increasing Preference for Enteral Nutrition will Restrain Market Growth Increasing Preference for Multi-chamber Bags Decreases Cost of Therapy Parenteral Nutrition Market to Geographical Landscape Revenues by Geographical Segmentation The US Sales Value Nutrient Market Segmentation Key Products Top Five Countries in Europe Sales Value Nutrient Market Segmentation Key Products Japan Sales Value Nutrient Market Segmentation Key Products Parenteral Nutrition Market to Nutrient Market Segmentation Overview Amino Acids Market Global Sales Value Sales Value by Geography Lipids Market Global Sales Value Sales Value by Geography Carbohydrates Market Global Sales Value Sales Value by Geography Additives Market Global Sales Value Sales Value by Geography Parenteral Nutrition Market - Marketed Products Baxter International Inc OLIMEL...33 Page 5

5 Table of Contents Clinimix ClinOleic 20% Clinisol 15% B. Braun Melsungen AG NuTRIflex System Lipofundin Aminoplasmal FreAmine III Fresenius Kabi AG Intralipid SmofKabiven Dipeptiven Omegaven Hospira, Inc Aminosyn Liposyn Otsuka Pharmaceutical Factory Inc Elneopa Neoparen B-Fluid Terumo Corporation Unicaliq Fulcaliq Parenteral Nutrition Market to Competitive Landscape Market Share Analysis: Parenteral Nutrition Competitive Profiling Baxter International Inc B. Braun Melsungen AG Fresenius Kabi AG Hospira, Inc Otsuka Pharmaceutical Factory Inc Terumo Corporation Parenteral Nutrition Market to Strategic Consolidations Overview Major Acquisitions in the Parenteral Nutrition Market Baxter International Completes Acquisition of Prism Pharma for $338m in April Baxter Acquires Willow Healthcare Services in July Fresenius Acquires Novartis Nutrition and Nestle Espana in December Fresenius Kabi Acquires Infusia A.S. in December Fresenius Kabi Acquires Clinico GmbH in October Fresenius Kabi Acquires Isotec Nutrition from Alliance Pharmaceuticals in May Hospira Acquires Clayton Manufacturing Facility from Fresenius Kabi in June Major Agreements in the Parenteral Nutrition Market Baxter Signs Agreement with Hanmi Pharmaceuticals in December Hospira Signs a Five-year Agreement with Novation in October B. Braun Signs Agreement with Amerinet Inc in October B. Braun Signs Agreement with Premier Purchasing Partners in August Hospira Announces New Contract with Premier Purchasing Partners in August Hospira Announces New Contract with HealthTrust Purchasing Group in February Baxter and Novation Sign Two-year Contract Extension in October Baxter Announces Plans to Form Parenteral Nutrition Joint Venture with Baiyunshan in China in August Page 6

6 Table of Contents B. Braun Signs Agreement with Curlin Medical in March Fresenius Kabi and Pharmatel Pty Ltd. Formed a Joint Venture in September Parenteral Nutrition Market to Appendix Market Definitions Abbreviations Bibliography Research Methodology Coverage Secondary Research Primary Research Section Methodology Expert Panel Validation Contact Us Disclaimer...71 Page 7

7 Table of Contents 1.1 List of Tables Table 1: Parenteral Nutrition Market, Global, Nutritional Status Assessment, Table 2: Parenteral Nutrition Market, The US, A.S.P.E.N. Guidelines for Parenteral Nutrition, Table 3: Parenteral Nutrition Market, Global, Revenues ($m), Table 4: Parenteral Nutrition Market, Global, Revenue Forecasts ($m), Table 5: Parenteral Nutrition Market, Global, Revenue by Geographical Segmentation ($m), Table 6: Parenteral Nutrition Market, Global, Revenue Forecasts by Geographical Segmentation ($m), Table 7: Parenteral Nutrition Market, The US, Revenues ($m), Table 8: Parenteral Nutrition Market, The US, Revenue Forecasts ($m), Table 9: Parenteral Nutrition Market, Top Five Countries of Europe, Revenues ($m), Table 10: Parenteral Nutrition Market, Top Five Countries of Europe, Revenue Forecasts ($m), Table 11: Parenteral Nutrition Market, Japan, Revenues ($m), Table 12: Parenteral Nutrition Market, Japan, Revenue Forecasts ($m), Table 13: Parenteral Nutrition Market, Amino Acids Revenue by Geographical Segmentation ($m), Table 14: Parenteral Nutrition Market, Lipids Revenue by Geographical Segmentation ($m), Table 15: Parenteral Nutrition Market, Carbohydrates Revenue by Geographical Segmentation ($m), Table 16: Parenteral Nutrition Market, Additives Revenue by Geographical Segmentation ($m), Table 17: Parenteral Nutrition Market, Global, Product Composition - Lipofundin, Table 18: Parenteral Nutrition Market, Global, Product Composition - Aminoplasmal, Table 19: Parenteral Nutrition Market, Global, Product Composition - Aminosyn, Table 20: Parenteral Nutrition Market, Global, Strategic Consolidations Overview, Page 8

8 Table of Contents 1.2 List of Figures Figure 1: Parenteral Nutrition Market, Global, Nutritional Support Algorithm...12 Figure 2: Parenteral Nutrition Market, Global, Nutrition Requirements for TPN, Figure 3: Parenteral Nutrition Market, Global, Revenues ($m), Figure 4: Parenteral Nutrition Market, Global, Drivers and Barriers, Figure 5: Parenteral Nutrition Market, Global, Revenue by Geographical Segmentation ($m), Figure 6: Parenteral Nutrition Market, The US, Historic Revenue and Forecasts ($m), Figure 7: Parenteral Nutrition Market, The US, Key Products, Figure 8: Parenteral Nutrition Market, Top Five Countries of Europe, Historic Revenue and Forecasts ($m), Figure 9: Parenteral Nutrition Market, Top Five Countries in Europe, Key Products, Figure 10: Parenteral Nutrition Market, Japan, Revenue Forecasts ($m), Figure 11: Parenteral Nutrition Market, Japan, Key Products, Figure 12: Parenteral Nutrition Market, Global, Nutrient Market Segmentation (%), Figure 13: Parenteral Nutrition Market, Amino Acids Revenue by Geographical Segmentation ($m), Figure 14: Parenteral Nutrition Market, Lipids Revenue by Geographical Segmentation ($m), Figure 15: Parenteral Nutrition Market, Carbohydrates Revenue by Geographical Segmentation ($m), Figure 16: Parenteral Nutrition Market, Additives Revenue by Geographical Segmentation ($m), Figure 17: Parenteral Nutrition Market, Global, Product Profile - OLIMEL, Figure 18: Parenteral Nutrition Market, Global, Product Profile - Clinimix, Figure 19: Parenteral Nutrition Market, Global, Product Profile - ClinOleic 20%, Figure 20: Parenteral Nutrition Market, Global, Product Profile - Clinisol 15%, Figure 21: Parenteral Nutrition Market, Global, Product Profile - NuTRIflex, Figure 22: Parenteral Nutrition Market, Global, Product Profile - Lipofundin, Figure 23: Parenteral Nutrition Market, Global, Product Profile - Aminoplasmal, Figure 24: Parenteral Nutrition Market, Global, Product Profile - FreAmine III, Figure 25: Parenteral Nutrition Market, Global, Product Profile-Intralipid, Figure 26: Parenteral Nutrition Market, Global, Product Profile - SmofKabiven, Figure 27: Parenteral Nutrition Market, Global, Product Profile - Dipeptiven, Figure 28: Parenteral Nutrition Market, Global, Product Profile - Omegaven, Figure 29: Parenteral Nutrition Market, Global, Product Profile - Aminosyn, Figure 30: Parenteral Nutrition Market, Global, Product Profile - Liposyn, Figure 31: Parenteral Nutrition Market, Global, Product Profile - Neoparen, Figure 32: Parenteral Nutrition Market, Global, Product Profile - B-Fluid, Figure 33: Parenteral Nutrition Market, Global, Product Profile - Unicaliq, Figure 34: Parenteral Nutrition Market, Global, Product Profile - Fulcaliq, Figure 35: Parenteral Nutrition Market, Global, Market Share of Top Manufacturers (%), Figure 36: Parenteral Nutrition Market to 2018, Global, Company Profile - Baxter International Inc., Figure 37: Parenteral Nutrition Market, Global, SWOT Analysis - Baxter International Inc., Figure 38: Parenteral Nutrition Market to 2018, Global, Company Profile - B. Braun Melsungen AG, Figure 39: Parenteral Nutrition Market, Global, SWOT Analysis - B. Braun Melsungen AG, Figure 40: Parenteral Nutrition Market, Global, Company Profile - Fresenius Kabi AG, Figure 41: Parenteral Nutrition Market, Global, SWOT Analysis - Fresenius Kabi AG, Figure 42: Parenteral Nutrition Market, Global, Company Profile - Hospira Inc., Figure 43: Parenteral Nutrition Market, Global, SWOT Analysis - Hospira Inc., Figure 44: Parenteral Nutrition Market, Global, Company Profile - Otsuka Pharmaceutical Factory Inc., Figure 45: Parenteral Nutrition Market, Global, Company Profile - Terumo Corporation, Figure 46: Parenteral Nutrition Market, Global, Strategic Consolidations Overview (%), Page 9

9 Parenteral Nutrition Market to 2018: Introduction 2 Parenteral Nutrition Market to Introduction The global PN market is growing rapidly, with increasing incidence of diseases such as cancer, AIDS (Acquired Immunodeficiency Syndrome) and GI (Gastrointestinal) disorders, including short bowel syndrome, ischemic bowel disease, pseudo obstruction and Crohn s disease. The other major factor driving the growth of the global PN market is the increase in the elderly population in developed countries. In 2011, the global PN market was estimated to be worth $XXm, representing a Compound Annual Growth Rate (CAGR) of XX% between 2004 and The US market, with sales worth $XXm in 2011, accounted for XX% of the total PN market. The market in the top five countries in Europe was estimated to be $XXm, the second largest PN market, and to have grown at a CAGR of XX% between 2004 and The PN market in Japan registered a share of XX% of the total PN market, accounting for $XXm in sales value in By 2018, the global PN market is forecast to be worth $XXm, representing a CAGR of XX% between 2011 and The US is expected to remain the largest market segment, with $XXm of sales in The PN market in the top five countries in Europe will be the second largest segment, with $XXm in revenues by Japan, which was the smallest segment in 2011, is expected to register sales of $XXm in 2018, indicating a CAGR of XX% between 2011 and The PN market Merger and Acquisitions (M&As) landscape demonstrated a fairly moderate level of activity between 2004 and 2011, with XX major acquisition deals signed during the period. Of the big pharmaceutical companies that witnessed acquisition activity, Fresenius Kabi was the most involved, participating in XX out of the XX M&A deals. In addition, a strategic analysis of the licensing agreements reveals that the agreements were carried out with the objective of expanding presence in worldwide PN markets. Overall, the PN market is very attractive and is poised for high growth between 2011 and Page 10

10 Parenteral Nutrition Market to 2018: Geographical Landscape 5.2 The US Sales Value In 2011, the PN market in the US was estimated at $XXm, indicating a CAGR of XX% between 2004 and The growth in the elderly population and an increase in the incidence of diseases that require PN as nutritional support are the major factors responsible for the high growth of the market. The figure below is an illustration of the US revenue data and forecasts for Figure 6: Parenteral Nutrition Market, The US, Historic Revenue and Forecasts ($m), CAGR ( ): XX% CAGR ( ): XX% Revenues ($m) Source: GBI Research, GBI Research Proprietary Database [Accessed May 5, 2012] Table 7: Parenteral Nutrition Market, The US, Revenues ($m), Year CAGR (%) Revenues ($m) Source: GBI Research, GBI Research Proprietary Database [Accessed May 5, 2012] Table 8: Parenteral Nutrition Market, The US, Revenue Forecasts ($m), Year CAGR (%) The US ($m) Source: GBI Research, GBI Research Proprietary Database [Accessed May 5, 2012] There were a total of XX PN infusions in acute care in-patients in the US in 2007, a rise from XX PN infusions in 2005 (ASPEN, 2010). The rapid uptake of amino acid solutions such as Aminosyn, lipid emulsions such as Liposyn and MCBs such as Clinimix and Clinimix E over the past decade contributed to the market growth. In addition, an increased awareness of PN among physicians and other healthcare professionals has resulted in an increase in the number of people being prescribed PN. Page 22

11 Parenteral Nutrition Market to 2018: Strategic Consolidations 9 Parenteral Nutrition Market to Strategic Consolidations 9.1 Overview The figure illustrates the major companies actively involved in strategic consolidations in Figure 46: Parenteral Nutrition Market, Global, Strategic Consolidations Overview (%), 2012 Hospira Baxter B.Braun Fresenius Kabi Source: GBI Research, GBI Research s Proprietary Database [Accessed on May 10, 2012] Table 20: Parenteral Nutrition Market, Global, Strategic Consolidations Overview, 2012 Company Number of Strategic Consolidations B. Braun Hospira Fresenius Kabi Baxter Total Source: GBI Research, GBI Research s Proprietary Database [Accessed on May 10, 2012] Page 63

12 Parenteral Nutrition Market to 2018: Appendix 10 Parenteral Nutrition Market to Appendix 10.1 Market Definitions The global PN market refers to the top seven markets, namely the US, the UK, Germany, France, Spain, Italy and Japan. Diseased Population: this refers to the estimated number of people who are affected by diseases such as cancer, AIDS and GI disorders that require PN as nutritional support. Prescription Population: this refers to the number of people that are on PN therapy. Nutritional support: nutritional support is The provision of nutrients orally, enterally, or parenterally with therapeutic intent. This includes, but is not limited to, provision of total enteral or PN support, and provision of therapeutic nutrients to maintain and /or restore optimal nutrition status and health (ASPEN, 2005) Abbreviations ASPEN.: American Society for Parenteral and Enteral Nutrition AIDS: BMI: BPNG: CAGR: CDC: CN: Acquired Immunodeficiency Syndrome Body Mass Index British Pharmaceutical Nutrition Group Cumulative Annual Growth Rate Centers for Disease Control and Prevention Clinical Nutrition COM PN: Compounded Parenteral Nutrition CVC: EN: EPUFA: FDA: Central Venous Catheter Enteral Nutrition Essential Poly-Unsaturated Fatty Acids Food and Drug Administration g/kg/day: grams per kilogram per day GI: HPN: ICU: IDE: IV: JPEN: LOS: M&A: MCBs: Gastro-intestinal Home Parenteral Nutrition Intensive Care Units Investigational Device Exemption Intravenous Journal of Parenteral and Enteral Nutrition Length of Stay Mergers and Acquisitions Multi-Chamber Bags MCT/LCT: Medium Chain Triglycerides and Long Chain Triglycerides MHRA: MUFA: MUST: Medicines and Healthcare products Regulatory Agency Mono-unsaturated Fatty Acids Malnutrition Universal Screening Tool mosm/l: Milliosmole/liter Page 68

13 Parenteral Nutrition Market to 2018: Appendix NHS: OPM: PN: R&D: SFA: SGA: TPN: National Health Service Out Patient Market Parenteral Nutrition Research and Development Saturated Fatty Acids Subjective Global Assessment Total Parenteral Nutrition 10.3 Bibliography The following sources were referred to build this report: ASPEN (2012). ASPEN. Documents Library Table of Contents. American Society for Parenteral and Enteral Nutrition. Available from: [Accessed on May 5, 2012]. Baxter (2012a). Olimel Product Information. Baxter. Available from: Baxter (2012b). Clinoleic 20% Product Information. Baxter. Available from: Baxter (2012c). Clinisol 15% Product Information. Baxter. Available from: aea74c29e66d44e724969dbd81e1c159&pid= [Accessed on May 6, 2012] B. Braun (2012a). Nutriflex System Product Information. B. Braun. Available from: [Accessed on May 6, 2012]. B. Braun (2012b). Lipofundin Product Information. B. Braun. Available from: [Accessed on May 6, 2012]. B. Braun (2012c). Aminoplasmal Product Information. B. Braun. Available from: [Accessed on May 6, 2012]. Claris Lifesciences (2012). Nutrition. Claris Lifesciences. Available from: [Accessed on May 6, 2012]. Clinimix (2012). Product Information. Clinimix. Available from: PI.pdf. FDA (2012). Drugsat_Docs. Food and Drug Administration. Available from: Hospira (2012). Products. Hospira. Available from: [Accessed on May 6, 2012]. Hospira (2012). Products. Hospira. Available from: [Accessed on May 6, 2012]. Mirtallo J, et al. (2004). Safe Practices for Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 28(6):S39-S70. Otsuka Pharmaceutical (2009). Release. Otsuko. Available from: [Accessed on May 6, 2012]. The Merck Manual (2012). Nutritional Disorders. Available from: ral_nutrition_tpn.html - global nutrition guidelines for TPN. [Accessed on May 3, 2012]. Page 69

14 Parenteral Nutrition Market to 2018: Appendix Terumo Corporation (2012). About us. Terumo. Available from: [Accessed on May 3, 2012] Research Methodology GBI Research s dedicated research and analysis teams consist of experienced professionals with a pedigree in marketing, market research, consulting backgrounds in the medical devices industry and advanced statistical expertise. GBI Research adheres to the codes of practice of the Market Research Society ( and the Strategic and Competitive Intelligence Professionals ( All GBI Research databases are continuously updated and revised. The following research methodology is followed for all databases and reports Coverage The objective of updating GBI Research s coverage is to ensure that it represents the most up to date vision of the industry possible. Changes to the industry taxonomy are built on the basis of extensive research of company, association and competitor sources. Company coverage is based on three key factors: Revenues, products and media attention/innovation/market potential. The estimated revenues of all major companies, including private and governmental, are gathered and used to prioritize coverage. Companies which are making the news, or which are of particular interest due to their innovative approach, are prioritized. GBI Research aims to cover all major news events and deals in the pharmaceutical industry, updated on a daily basis. The coverage is further streamlined and strengthened with additional inputs from GBI Research s Expert Panel (see below) Secondary Research Secondary research was carried out on internal and external sources to source qualitative and quantitative information in the report. The secondary research sources that are referred to in this report include but are not limited to: Company websites, annual reports, financial reports, investor presentations and US Securities and Exchanges (SEC) filings for the 20 companies covered in this report; Industry trade journals, scientific journals and other technical literature Relevant patent and regulatory databases National government documents, statistical databases and market reports News articles, press releases and web-casts specific to the companies operating in the market Primary Research GBI Research conducts hundreds of primary interviews each year with industry participants and commentators, in order to validate its data and analysis. A typical research interview fulfills the following functions: It provides first-hand information on the market size, market trends, growth trends, competitive landscape and future outlook. Helps in validating and strengthening the secondary research findings Further develops the analysis team s expertise and market understanding Page 70

15 Parenteral Nutrition Market to 2018: Appendix Primary research involves interactions, telephone interviews, and face-to-face interviews for each market, category, segment and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to: Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers Outside experts: Research analysts specializing in specific parenteral nutrition Key Opinion Leaders: Researchers specializing in PN corresponding to different kinds of biodefense research Section Methodology The report consists of the following four major sections: Nutrient Market Segmentation - This section contains the sales value of amino acids, carbohydrates, lipids and additives for the US, the UK, France, Spain, Germany, Italy and Japan. Marketed Products - The product descriptions here were sourced from company websites and GBI research s proprietary database. Competitive Landscape - This chapter includes company profiles and SWOT analyses for major companies active in the PN market. This section is sourced from company websites, company annual reports and internal databases Expert Panel Validation GBI Research uses a panel of experts to cross-verify its databases and forecasts. GBI Research s expert panel comprises marketing managers, product specialists, international sales managers from medical device companies, academics from research universities, KOLs from hospitals, consultants from venture capital funds and distributors/suppliers of medical equipment and supplies. Historic data and forecasts are relayed to GBI Research s Expert Panel for feedback and adjusted in accordance with their feedback Disclaimer All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GBI Research. Page 71